Filing Analysis
Equillium, Inc. announced its financial results for the second quarter ended June 30, 2026. The filing serves as a formal notification of the earnings release via press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Announcement date: August 13, 2026.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Equillium, Inc. held its 2026 Annual Meeting of Stockholders on May 28, 2026, where shareholders approved several key amendments to the Certificate of Incorporation, most notably a reverse stock split and a significant increase in authorized shares.
🚩 Red Flags
- Approval of a reverse stock split (1-for-2 to 1-for-20) is a classic red flag for micro-cap companies, often used to artificially inflate share price to avoid Nasdaq delisting.
- Doubling the authorized share count (from 200M to 400M) creates significant potential for future shareholder dilution.
- Multiple high-impact items (reverse split and share authorization increase) approved in a single meeting.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio range of 1-for-2 to 1-for-20, to be determined by the Board of Directors.
- The authorized number of common stock shares was increased from 200,000,000 to 400,000,000 shares.
- Crowe LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The Board of Directors was reduced from seven members to six following the expiration of Peter Colabuono's term.
- Charles McDermott and Bruce Steel were elected as Class II directors.
Equillium, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information was furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing includes Exhibit 99.1, which is the press release containing the financial details.
Equillium, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The information was furnished via a press release and does not include any immediate material changes to corporate structure or auditor status.
📋 Key Facts
- Report date: March 25, 2026
- Financial period covered: Fourth quarter and full year ended December 31, 2025
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
- The report was signed by Bruce D. Steel, Chief Executive Officer
Equillium, Inc. entered into a securities purchase agreement for a private placement (PIPE) with RA Capital Healthcare Fund, L.P., raising approximately $35.0 million in gross proceeds. The transaction involves the sale of common stock and pre-funded warrants to fund the development of its EQ504 program and for general working capital.
🚩 Red Flags
- Substantial potential dilution from the issuance of over 17.6 million shares via pre-funded warrants.
- The securities are being sold in an unregistered private placement, bypassing standard public offering scrutiny.
📋 Key Facts
- Total gross proceeds of approximately $35.0 million from RA Capital Healthcare Fund, L.P.
- Issuance of 1,179,508 shares of common stock at $1.854 per share.
- Issuance of pre-funded warrants to purchase up to 17,698,593 shares at $1.8539 per warrant share.
- The purchase price was based on the five-day average closing price prior to the agreement.
- The company is required to file a resale registration statement within 30 days of closing.
- Closing is anticipated on or about March 13, 2026.
Equillium, Inc. announced its financial results for the third quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 13, 2025.
- The results were announced via a press release (Exhibit 99.1).
Equillium, Inc. has finalized the engagement of Crowe LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025. This filing serves as an amendment to a previous 8-K to confirm the completion of client acceptance procedures and the execution of the engagement letter.
🚩 Red Flags
- Auditor change (though no disagreement was noted, changes in micro-cap auditors often warrant scrutiny for potential underlying reporting issues).
📋 Key Facts
- Crowe LLP has been engaged as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Client acceptance procedures were completed on October 21, 2025.
- The Company and Crowe executed an engagement letter on October 21, 2025.
- No disagreements with previous auditors or consultations regarding specific accounting treatments were reported.
Equillium, Inc. has dismissed its independent auditor, KPMG LLP, and appointed Crowe LLP as its new auditor for the fiscal year ending December 31, 2025. The filing also notes significant board turnover and the termination of a major collaboration agreement with Biocon Limited.
🚩 Red Flags
- Auditor change (KPMG to Crowe) often signals friction or high audit costs in micro-caps.
- Ongoing 'going concern' qualification in recent audits due to significant operating losses and negative cash flows.
- Significant Board of Directors turnover (two resignations).
- Termination of a long-standing collaboration/license agreement with Biocon Limited.
📋 Key Facts
- KPMG LLP dismissed effective September 30, 2025.
- Crowe LLP appointed as the new independent registered public accounting firm for fiscal year 2025.
- Dr. Stephen Connelly and Dr. Bala Manian resigned from the Board of Directors effective October 1, 2025.
- The Board size was reduced from nine directors to seven directors.
- Dr. Stephen Connelly appointed as President; Daniel M. Bradbury transitioned from Executive Chairman to Chairman of the Board.
- Termination of collaboration and license agreement with Biocon Limited regarding itolizumab.
- Biocon will set off a $363,000 technical service fee against amounts owed by Equillium.
Equillium, Inc. has filed a prospectus supplement to increase the aggregate offering price of its common stock under an existing At-The-Market (ATM) sales agreement from $21.95 million to up to $75 million.
🚩 Red Flags
- Significant increase in potential dilution: The company is expanding its ATM capacity by over $53 million.
- Continuous capital needs: The use of an ATM program often indicates a need for ongoing liquidity to fund operations (burn rate management).
📋 Key Facts
- Increased total aggregate offering amount: Up to $75,000,000.
- Previous ATM capacity was $21,950,000 under the original Sales Agreement dated October 5, 2023.
- The company has previously sold 1,719,485 shares for gross proceeds of $0.96 million via this agreement.
- The offering is being conducted through an Open Market Sale Agreement with LifeSci Capital LLC (amended August 3, 2025).
- The sale is made pursuant to a Form S-3 Registration Statement.
Equillium, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This follows a period of non-compliance that began in December 2024.
🚩 Red Flags
- Historical delisting risk: The company was under threat of delisting for over six months due to sub-$1.00 trading prices.
- Volatility indicator: The need to meet a 10-day consecutive requirement suggests recent price volatility or a specific market event that pushed the stock above $1.00.
📋 Key Facts
- The Company met the Bid Price Rule requirement on August 28, 2025.
- Compliance was achieved by maintaining a closing bid price of $1.00 or more for at least 10 consecutive business days.
- Nasdaq officially notified the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The non-compliance issue originated from a notice received on December 13, 2024.
Equillium, Inc. entered into a Securities Purchase Agreement to conduct a two-stage private placement of common stock and pre-funded warrants totaling up to $50 million. The initial closing aims to raise $30 million at approximately $0.57 per share to fund EQ504 development and extend the cash runway through 2027.
🚩 Red Flags
- Significant dilution via issuance of millions of new shares and pre-funded warrants at a low share price ($0.57).
- Milestone trigger includes a high stock price requirement ($2.50), which is significantly above the current offering price, indicating a heavy dependency on clinical/market success.
- Pre-funded warrants allow investors to bypass 19.99% ownership limits but function similarly to common stock upon exercise.
📋 Key Facts
- Initial Closing: Expected ~August 12, 2025; involves selling 21,814,874 shares at $0.57/share and warrants for up to 30,816,705 warrant shares at $0.5699/warrant.
- Milestone Closing: Up to an additional $20 million if specific triggers are met (EQ504 IND clearance or dosing in Australia/NZ AND a stock price threshold of $2.50 VWAP).
Equillium, Inc. announced a strategic shift to integrate a cryptocurrency treasury reserve strategy while reporting limited cash reserves of $11.5 million as of June 30, 2025. The company explicitly stated that current cash is expected to only fund operations into the fourth quarter of 2025.
🚩 Red Flags
- Going concern risk: Explicit mention that current cash only funds operations into Q4 2025.
- Significant liquidity constraint: Only $11.5M in cash remaining for a biotech firm with clinical development goals.
- Pivot to high-volatility assets: Adoption of a cryptocurrency treasury strategy is often viewed as a sign of desperation for non-traditional capital/liquidity in micro-cap companies.
- Need for additional capital: Explicitly stated the need to raise more capital to fund EQ504 development and the crypto strategy.
📋 Key Facts
- Cash and cash equivalents totaled approximately $11.5 million as of June 30, 2025.
- Current cash runway is estimated to last only into the fourth quarter of 2025.
- The company has amended its investment policy to authorize the purchase of cryptocurrency as a treasury reserve strategy.
- LifeSci Capital LLC replaced Jefferies LLC as the sales agent under the existing ATM Agreement via Amendment No. 1 on August 3, 2025.
- Management is implementing operating changes to decrease expenditures and conserve cash.
Equillium, Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement ($1.00 per share). Failure to comply by December 8, 2025, may result in delisting.
🚩 Red Flags
- Delisting risk: Failure to meet minimum bid price by Dec 8, 2025, leads to potential delisting.
- Potential reverse stock split: Management explicitly mentioned this as a contemplated option to boost share price.
📋 Key Facts
- Received notice on June 12, 2025, granting an extension until December 8, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
- The company failed the Minimum Bid Price Requirement (stock below $1.00 for 30 consecutive business days) during the initial 180-day period ending June 11, 2025.
- Management is considering a reverse stock split as a potential method to regain compliance.
- The company's common stock continues to trade on the Nasdaq Capital Market under the symbol 'EQ'.
Equillium, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved a significant reverse stock split and an amendment to the 2018 Equity Incentive Plan.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-20), often used to maintain Nasdaq listing compliance or improve share price perception.
- Increase in authorized shares under the Equity Incentive Plan, which can lead to future dilution.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio range between 1-for-2 and 1-for-20.
- The Board of Directors retains sole discretion to determine the specific ratio and timing of the split.
- Stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing authorized shares by 1,781,000.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Three directors (Stephen Connelly, Bala S. Manian, and Barbara Troupin) were elected to Class I terms until 2028.
Equillium, Inc. announced its preliminary estimated cash, cash equivalents, and short-term investments as of March 31, 2025. The company reported approximately $14.5 million in liquidity for the period.
🚩 Red Flags
- Low liquidity position ($14.5M) relative to typical micro-cap operational burn rates in the biotech sector.
- Financial statements for the quarter are not yet finalized, indicating potential volatility in upcoming 10-Q filing.
📋 Key Facts
- Estimated cash, cash equivalents, and short-term investments as of March 31, 2025: ~$14.5 million.
- Actual financial statements for the quarter ended March 31, 2025, are not yet available.
- The reported figures are unaudited and subject to final closing procedures and adjustments.
Equillium, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fourth quarter and full year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Equillium, Inc. announced topline Phase 2 data for itolizumab in treating moderate to severe ulcerative colitis (UC). The study met its primary endpoint of clinical remission and showed favorable safety results compared to placebo and adalimumab.
🚩 Red Flags
- Baseline disease severity was higher in the itolizumab arm (23% severe) compared to placebo and adalimumab arms (0% severe).
📋 Key Facts
- Phase 2 study evaluated itolizumab (140 mg) vs. placebo and adalimumab in biologic-naïve UC patients.
- Primary endpoint: 23.3% clinical remission for itolizumab at 12 weeks vs. 20.0% for adalimumab and 10.0% for placebo.
- Secondary endpoint (clinical response): 63.3% for itolizumab vs. 60.0% for adalimumab and 46.7% for placebo at 12 weeks.
- Secondary endpoint (endoscopic remission): 16.7% for itolizumab, matching the adalimumab arm at 12 weeks.
- The study reported no significant safety signals; itolizumab was generally well tolerated.
Equillium, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock traded below $1.00 for 30 consecutive business days. The company has until June 11, 2025, to regain compliance through a ten-day period of trading at or above $1.00.
🚩 Red Flags
- Delisting notice (non-compliance with minimum bid price requirement).
- Explicit mention of considering a reverse stock split to regain compliance.
- Prolonged period (30 consecutive days) of trading below the $1.00 threshold.
📋 Key Facts
- Received Nasdaq notice on December 13, 2024, regarding non-compliance with Listing Rule 5550(a)(2).
- The deficiency is due to the common stock trading below $1.00 for 30 consecutive business days.
- The company has a 180-day grace period to regain compliance, expiring June 11, 2025.
- To cure the deficiency, the stock must meet or exceed $1.00 per share for at least ten consecutive business days during the grace period.
- A second 180-day extension may be available if certain market value and public float requirements are met.
Equillium, Inc. announced the immediate resignation of Yu (Katherine) Xu, Ph.D. from the Board of Directors and the Audit Committee. The company has appointed Barbara Troupin, M.D. to the Audit Committee and Peter Colabuono as a Class II director to fill the resulting vacancies.
🚩 Red Flags
- None identified; resignation was explicitly stated as not being due to disagreements.
📋 Key Facts
- Yu (Katherine) Xu, Ph.D. resigned from the Board and Audit Committee effective December 10, 2024.
- The company stated Dr. Xu's resignation is not due to any disagreement regarding operations, policies, or practices.
- Barbara Troupin, M.D. appointed to the Audit Committee on December 11, 2024.
- Peter Colabuono appointed as a Class II director with a term expiring at the 2026 annual meeting.
- Peter Colabuono granted an option to purchase 40,000 shares of common stock, vesting monthly over three years.
Equillium, Inc. announced its financial results for the third quarter ended September 30, 2024 via a press release. The filing is a standard earnings announcement under Item 2.02.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024
- Filing date: November 13, 2024
- The results were released via press release attached as Exhibit 99.1.
Equillium, Inc. announced the termination of its asset purchase agreement with Ono Pharmaceutical, resulting in the loss of a strategic option to acquire rights to itolizumab (EQ001). Concurrently, the company is pausing enrollment in its Phase 3 EQUATOR study and halting activities for other pipeline candidates (EQ101 and EQ302) to preserve cash runway into Q4 2025.
🚩 Red Flags
- Loss of a strategic partner/buyer (Ono Pharmaceutical) for the lead asset.
- Clinical trial pause: Temporary suspension of enrollment in a Phase 3 study is often viewed negatively by markets regarding program viability or data integrity risks.
- Pipeline contraction: Pausing EQ101 and EQ302 indicates significant resource constraints and narrowing focus due to capital limitations.
- Cash runway concerns: Explicit mention of 'taking operational steps to extend our cash runway' implies limited liquidity.
📋 Key Facts
- Ono Pharmaceutical's option to acquire rights to itolizumab (EQ001) has lapsed, effective October 30, 2024.
- Equillium retains all commercial rights to itolizumab (EQ001).
- The company is temporarily pausing enrollment in the Phase 3 EQUATOR study for acute graft-versus-host disease.
- The company aims to accelerate topline data for the EQUATOR study to Q1 2025 by reducing enrollment to ~150 patients.
- Operational pivot: itolizumab (EQ001) is now the top priority; activities for EQ101 and EQ302 are paused.
- Cash runway is being extended through Q4 2025 via these operational cost-cutting measures.
Equillium, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement. The company met the $1.00 per share threshold for 10 consecutive business days as of October 29, 2024.
🚩 Red Flags
- Historical non-compliance with Nasdaq's $1.00 minimum bid rule (previously disclosed in July 2024).
📋 Key Facts
- The Company received notice from Nasdaq on July 19, 2024, regarding non-compliance with the Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)).
- Compliance required a closing bid price of $1.00 or more for at least 10 consecutive business days.
- The Company met this requirement on October 29, 2024.
- The company has regained compliance with the minimum bid price requirement.
Equillium, Inc. announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Filing date: August 8, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Equillium, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock traded below $1.00 for 30 consecutive business days. The company has until January 15, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential for a reverse stock split (often dilutive or signal of distress)
- Persistent low share price (<$1.00) indicating market skepticism or capital constraints
📋 Key Facts
- Received Nasdaq notice on July 19, 2024, regarding non-compliance with Listing Rule 5550(a)(2).
- The deficiency is due to the common stock falling below $1.00 for 30 consecutive business days.
- The company has a 180-day grace period to regain compliance, expiring January 15, 2025.
- To cure the deficiency, the stock must trade at or above $1.00 for at least ten consecutive business days during the grace period.
- The company explicitly mentioned considering a reverse stock split as an option to regain compliance.
Equillium, Inc. provided a preliminary estimate of its cash, cash equivalents, and short-term investments as of June 30, 2024. The company noted that actual financial statements for the quarter are not yet finalized.
🚩 Red Flags
- Preliminary/unaudited data subject to final adjustments and closing procedures.
📋 Key Facts
- Estimated cash, cash equivalents, and short-term investments as of June 30, 2024: approximately $33.3 million.
- The reported figures are unaudited preliminary estimates.
- Actual financial statements for the quarter ended June 30, 2024 are not yet available.
Equillium, Inc. announced topline data from its Phase 2 proof-of-concept study of EQ101 for the treatment of alopecia areata (AA). The results demonstrated a favorable safety profile and signs of efficacy in achieving SALT score improvements.
🚩 Red Flags
- Small sample size (n=25 completed) limits statistical significance.
- High discontinuation rate: 11 out of 36 subjects discontinued early, though only 5 were attributed to adverse events.
📋 Key Facts
- Phase 2 single-dose study of EQ101 in adult patients with moderate to very-severe alopecia areata.
- Safety: No serious adverse events (SAEs) reported; 98.9% of adverse events were Grade 1 or 2.
- Efficacy: 20% of subjects completing 24 weeks achieved a SALT score ≤ 20 (where lower is better).
- In the moderate-to-severe subgroup (SALT 35 to <95), 29% achieved a SALT score ≤ 20 by week 24.
- The study enrolled 36 subjects; 25 completed the 24-week treatment period.
- Mean SALT improvement from baseline for those completing the study was 18%.
- Preliminary data indicated target engagement via reductions of cell surface CD132 on CD8 and NK cells.
Equillium, Inc. held its 2024 Annual Meeting of Stockholders where shareholders approved a proposal to effect a reverse stock split with a ratio between 1-for-2 and 1-for-10. The meeting also resulted in the election of three Class III directors and the ratification of KPMG LLP as independent auditors.
🚩 Red Flags
- Approval of a reverse stock split (often used to maintain Nasdaq listing compliance or improve share price).
📋 Key Facts
- Annual Meeting held on May 22, 2024.
- Shareholders approved a reverse stock split ratio between 1-for-2 and 1-for-10.
- Election of Daniel M. Bradbury, Martha J. Demski, and Mark Pruzanski, M.D. as Class III directors.
- Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Advisory vote approved executive compensation (Say-on-Pay).
- Shareholders indicated a preference for stockholder advisory votes on executive compensation every three years.
Equillium, Inc. announced its financial results for the first quarter ended March 31, 2024 via a press release. This is a routine earnings announcement filing.
📋 Key Facts
- Reporting period: First quarter ended March 31, 2024
- Announcement date: May 9, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
Equillium announced positive topline data from the Phase 1b EQUALISE study for itolizumab in treating lupus nephritis. The results showed high response rates and significant reduction in urine protein creatinine ratio (UPCR), potentially triggering a partnership milestone with Ono Pharmaceutical Co., Ltd.
📋 Key Facts
- Phase 1b EQUALISE study Type B portion reported positive topline data for itolizumab in lupus nephritis patients.
- Median spot UPCR reduction from baseline was approximately 73%.
- Clinical response rates: 37.5% (6 of 16) achieved Complete Response (CR); 43.8% (7 of 16) achieved Partial Response (PR).
- Data represents the first of two data set triggers for partner Ono Pharmaceutical Co., Ltd. to decide on exercising an option to acquire itolizumab.
- Ono's decision is expected in the second half of 2024.
- Safety profile: Most adverse events were mild (Grade 1) or moderate (Grade 2); no serious adverse events were related to study treatment.
Equillium, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2023. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2023.
- Announcement date: March 25, 2024.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Equillium, Inc. announced the appointment of Penny Tom as Principal Accounting Officer to succeed Jason Keyes in that specific capacity. The filing also notes the adoption of a 2024 Inducement Plan reserving 1.5 million shares for new hires.
🚩 Red Flags
- Internal reshuffling of financial leadership (though the CFO remains in place, the separation of the PAO role is noted).
📋 Key Facts
- Penny Tom appointed as Principal Accounting Officer on March 6, 2024.
- Jason Keyes remains CFO; he is only stepping down from the Principal Accounting Officer role.
- The Board approved a 2024 Inducement Plan to reserve 1,500,000 shares of common stock for new employees/directors.
- Inducement Plan was adopted without stockholder approval per Nasdaq Listing Rule 5635(c)(4).
Equillium, Inc. announced a prospectus supplement to increase its ATM (At-the-Market) offering capacity by up to $21.95 million and provided preliminary unaudited cash position estimates for year-end 2023.
🚩 Red Flags
- Increased ATM offering size suggests a need for immediate liquidity/capital raising.
- Preliminary financial data is unaudited and subject to significant adjustment during year-end closing procedures.
📋 Key Facts
- Company expects to report approximately $40.9 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
- The company filed a Prospectus Supplement for the offer and sale of common stock up to an aggregate price of $21,950,000.
- The offering is being conducted via an Open Market Sale Agreement with Jefferies LLC dated October 5, 2023.
- This supplement increases the previous offering capacity from $6.34 million to $21.95 million.
Equillium, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement. The company met the $1.00 per share threshold for 10 consecutive business days as of February 20, 2024.
🚩 Red Flags
- Historical delisting risk (the reason for this filing was a previous failure to meet the $1.00 minimum bid price requirement).
📋 Key Facts
- Nasdaq notified the Company on February 21, 2024, that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the 'Bid Price Rule').
- Compliance was achieved after maintaining a closing bid price of $1.00 or more for at least 10 consecutive business days.
- The requirement was officially met on February 20, 2024.
- The company had previously been in non-compliance since receiving notice on April 5, 2023.